A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02711553

Recruitment Status : Active, not recruiting

First Posted : March 17, 2016

Last Update Posted : August 25, 2020

Sponsor:

Information provided by (Responsible Party):

Eli Lilly and Company

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	February 16, 2018
Estimated Study Completion Date :	December 31, 2021
Certification/Extension First Submitted :	February 8, 2019

To Top